Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06548100 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
A Phase 3 study of Generalized Lipodystrophy, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT06548100 is a Phase 3 study of Generalized Lipodystrophy that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 9 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06548100, a Phase 3 study of Generalized Lipodystrophy, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switching from treatment with metreleptin. The study is looking at several other research questions, including: * What side effects may happen from taking mibavademab * How much mibavademab is in the blood at different times * Whether the body makes antibodies against mibavademab (which could make mibavademab less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG mibavademab
Study Locations (2)
Maryland
- National Institutes of Health - Bethesda
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2026-11-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06548100
The ClinicalTrials.gov registry entry for NCT06548100 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Lipodystrophy appearing as the primary indexed condition, and to 1 intervention - of which mibavademab is the first listed.
NCT06548100 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT06548100 about?
NCT06548100 is a clinical study titled "A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)". This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switc...
What is the current status of trial NCT06548100?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2024-12-16. Estimated completion is 2026-11-03.
What conditions does trial NCT06548100 study?
This clinical trial studies the following conditions: Generalized Lipodystrophy.
What interventions are being tested in trial NCT06548100?
The interventions under investigation include: mibavademab (DRUG).
Who is sponsoring clinical trial NCT06548100?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06548100 being conducted?
This trial has 2 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.